Metabolism drugs are prescription medications that help regulate and normalize an individual's metabolism. Products like Adderall, Vyvanse, and Ritalin help manage conditions like attention deficit hyperactivity disorder by slowing down the central nervous system and allowing for improved focus and concentration. Metformin is commonly prescribed to treat type 2 diabetes by helping regulate blood sugar levels. The need for effective medication management of chronic health issues is driving demand for metabolism drugs.
The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of chronic metabolic disorders is one of the key factors contributing to the growth of the metabolism drugs market. These conditions like diabetes and obesity have been on the rise globally due to poor dietary and lifestyle choices. It is estimated that over 420 million people worldwide have diabetes, with the number expected to rise to over 620 million by 2040. Similarly, worldwide obesity rates have nearly tripled since 1975 according to the World Health Organization. As more people develop metabolic issues, the demand for effective medication options will continue surging over the forecast period. Managing chronic diseases also economically impacts healthcare systems, pushing for more innovative drug formulations that can help curb the costs associated with these conditions over the long run.
Segment Analysis
The global Metabolism Drugs Market is dominated by the anti-obesity drugs segment. These drugs help in weight management and reduce the risk of obesity-related diseases like diabetes and heart diseases. They work by either suppressing appetite or increasing feeling of fullness. Some of the popular anti-obesity drugs are orlistat, lorcaserin, phentermine, liraglutide etc. The anti-obesity drugs segment holds around 35% of the total metabolism drugs market share owing to the rising global prevalence of obesity disorders.
Key Takeaways
The Global Metabolism Drugs Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.
Regional analysis: North America region currently dominates the global metabolism drugs market share and is expected to continue its dominance over the forecast period. This is attributable to the growing obese population in countries like the US and Canada coupled with high healthcare expenditure in the region. The Asia Pacific region is expected to witness the fastest growth during the forecast period owing to rising lifestyle diseases and increasing disposable incomes in emerging economies like India and China.
Key players: Key players operating in the metabolism drugs market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd€TMs Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma. These players are focusing on new product launches, expanding their regional presence and acquiring other players to gain maximum revenue share in this high growth market.
Get more insights on this topic:
https://www.dailyprbulletin.com/metabolism-drugs-market-insights/
This report contains market size and forecasts of Metabolism Drugs in global, including the following market information: Global Metabolism Drugs Market Revenue, 2016-2021, 2022-2027, ($ millions) Global Metabolism Drugs Market Sales, 2016-2021, 2022-2027, (K Units) Global top five Metabolism Drugs companies in 2020 (%)The global Metabolism Drugs market was valued at 15840 million in 2020 and is projected to reach US$ 19300 million by 2027, at a CAGR of 5.1% during the forecast period.We Surveyed the Metabolism Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.Download FREE Sample of this Report @ https://www.statsmarketresearch.com/download-free-sample/6515001/global-metabolism-drugs-2021-2027-503Total Market by Segment:Global Metabolism Drugs Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)Global Metabolism Drugs Market Segment Percentages, By Type, 2020 (%)Glycogen Metabolism Disease DrugLipid Metabolism Disease DrugAmino Acid Metabolism DrugOtherGlobal Metabolism Drugs Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)Global Metabolism Drugs Market Segment Percentages, By Application, 2020 (%)HospitalRetail PharmacyGlobal Metabolism Drugs Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions) & (K Units)Global Metabolism Drugs Market Segment Percentages, By Region and Country, 2020 (%)North AmericaUSCanadaMexicoEuropeGermanyFranceU.K.ItalyRussiaNordic CountriesBeneluxRest of EuropeAsiaChinaJapanSouth KoreaSoutheast AsiaIndiaRest of AsiaSouth AmericaBrazilArgentinaRest of South AmericaMiddle East & AfricaTurkeyIsraelSaudi ArabiaUAERest of Middle East & AfricaCompetitor AnalysisThe report also provides analysis of leading market participants including:Key companies Metabolism Drugs revenues in global market, 2016-2021 (Estimated), ($ millions)Key companies Metabolism Drugs revenues share in global market, 2020 (%)Key companies Metabolism Drugs sales in global market, 2016-2021 (Estimated), (K Units)Key companies Metabolism Drugs sales share in global market, 2020 (%)Further, the report presents profiles of competitors in the market, key players include:MerckNovartisTakeda PharmaceuticalAstra ZenecaBeohrigher IngelheimKOWAKytheraFuji yakuhinLG Life ScienceMetsubishi Tanabe PharmaReasons to Purchase Our Research Report:Analyzing the outlook of the market with the recent trends and SWOT analysisMarket dynamics scenario, along with growth opportunities of the market in the years to comeMarket segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspectsRegional and country-level analysis integrating the demand and supply forces that are influencing the growth of the market.Market value (USD Million) and volume (Units Million) data for each segment and sub-segmentCompetitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five yearsComprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market playersAnalyst support, along with the data support in excel format.Get the Complete Report & TOC @ https://www.statsmarketresearch.com/global-metabolism-drugs-2021-2027-503-6515001
Global Metabolism Drugs Market by Manufacturers, Countries, Type and Application, Forecast to 2023 Report “ Provides In-Depth Analysis Of Parent Market Trends, Macro-Economic Indicators And Governing Factors Along With Market Attractiveness As Per Segments.Introduction:Metabolism Drugs is used to treat the metabolic disease in humans.
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.Scope of the Global Metabolism Drugs Market ReportThis report focuses on the Metabolism Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa.
This report categorizes the market based on manufacturers, regions, type and application.Request a Sample of this Report @ http://www.orbisresearch.com/contacts/request-sample/2184933 The worldwide market for Metabolism Drugs is expected to grow at a CAGR of roughly 5.4% over the next five years, will reach 17900 million US$ in 2023, from 13100 million US$ in 2017, according to a new GIR (Global Info Research) study.USA is the largest supplier of Metabolism Drugs, with production revenue market share over 43%, while the sales market share is 40% in 2015.
Japan is an important market of Drugs for Metabolism Drugs in Asia, accounting for 9% production revenue market share and 10% sales revenue market share of global market.
Browse the Full Report @ http://www.orbisresearch.com/reports/index/global-metabolism-drugs-market-by-manufacturers-regions-type-and-application-forecast-to-2023 This report covers Analysis of Global Metabolism Drugs Market Segment by ManufacturersBioray Spritual River Natures Way Elite, LLC Acupeds Thermo Fisher Scientific IncGlobal Metabolism Drugs Market Segment by regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Columbia etc.
) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Make an enquiry before buying this report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2184933 Global Metabolism Drugs Market Segment by TypeGlycogen Metabolism Disease Drug Lipid Metabolism Disease Drug Amino Acid Metabolism Drug OtherGlobal Metabolism Drugs Market Segment by Applications, can be divided intoHospital Retail PharmacySome of the Points cover in Global Metabolism Drugs Market Research Report is:Chapter 1: Describe Metabolism Drugs Industry Introduction,Product Scope,Market Overview,Market Opportunities,Market Risk,Market Driving ForceChapter 2: To analyze the top manufacturers of Metabolism Drugs Industry in 2016 and 2017SalesRevenue and priceChapter 3: Competitive analysis among the top manufacturers in 2016 and 2017SalesRevenue and market shareChapter 4: Global Metabolism Drugs Market by regions from 2013 to 2018SalesRevenue and market shareChapter 5, 6, 7 and 8: Global Metabolism Drugs Market by key countries in these regionsSalesRevenue and market shareChapter 9 and 10: Global Metabolism Drugs Market by type and application from 2013 to 2018SalesRevenue and market shareGrowth rateChapter 11:Metabolism Drugs Industry Market forecast from 2018 to 2023RegionsType and application with sales and revenueChapter 12 and 13:Metabolism Drugs Industry Sales channelDistributorsTraders and dealersAppendixData sourceAbout Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements.
